It is made available under a CC-BY-ND 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.06.13.22276333;](https://doi.org/10.1101/2022.06.13.22276333) this version posted June 16, 2022. The copyright holder for this preprint

# 1 **An exploratory assessment of the impact of a novel risk assessment test on**

# 2 **breast cancer clinic waiting times and workflow: a discrete event**

# 3 **simulation model**

- 4 **Authors:** Alison F. Smith<sup>1,2</sup>, Samuel N. Frempong<sup>1,2</sup>, Nisha Sharma<sup>3</sup>, Richard
- 5 D. Neal<sup>1</sup>, Louise Hick<sup>2,3</sup>, Bethany Shinkins<sup>1,2</sup>

# 6 **Affiliations**

- 7 1. Leeds Institute of Health Sciences (LIHS), University of Leeds, Leeds, UK.
- 8 2. NIHR Leeds In-Vitro Diagnostics Evidence Co-operative (MIC)
- 9 3. Leeds Teaching Hospitals NHS Trust (LTHT), Leeds, UK.

## 10 **Corresponding Author**

- 11 Dr Alison F Smith
- 12 Lecturer
- 13 Academic Unit of Health Economics,
- 14 Leeds Institute of Health Sciences,
- 15 University of Leeds,
- 16 Leeds,
- 17 LS2 9NL
- 18 Email: a.f.c.smith@leeds.ac.uk

# 19 **Abstract**

20 **Background:** Breast cancer clinics across the UK have long been struggling to cope with high 21 demand. Novel risk prediction tools – such as the PinPoint test – could help to reduce unnecessary 22 clinic referrals. Using early data on the expected accuracy of the test, we explore the potential impact 23 of PinPoint on: (a) the percentage of patients meeting the two-week referral target, and (b) the number 24 of clinic 'overspill' appointments generated.

25 **Methods:** A simulation model was built to reflect the annual flow of patients through a single UK 26 clinic. Due to current uncertainty around the exact impact of PinPoint testing on standard care, two 27 primary scenarios were assessed. Scenario 1 assumed complete GP adherence to testing, with only 28 non-referred cancerous cases returning for delayed referral. Scenario 2 assumed GPs would overrule 29 20% of low-risk results, and that 10% of non-referred non-cancerous cases would also return for 30 delayed referral. A range of sensitivity analyses were conducted to explore the impact of key 31 uncertainties on the model results. Service reconfiguration scenarios, removing individual weekly 32 clinics from the clinic schedule, were also explored.

33 **Results:** Under standard care, 66.3% (95% CI: 66.0 to 66.5) of patients met the referral target, with 34 1,685 (1,648 to 1,722) overspill appointments. Under both PinPoint scenarios, >98% of patients met 35 the referral target, with overspill appointments reduced to between 727 (707 to 746) [Scenario 1] and 36 886 (861 to 911) [Scenario 2]. The reduced clinic demand was sufficient to allow removal of one 37 weekly low-capacity clinic [N=10], and the results were robust to sensitivity analyses.

38 **Conclusions:** The findings from this early analysis indicate that risk prediction tools could have the 39 potential to alleviate pressure on cancer clinics, and are expected to have increased utility in the wake 40 of heightened pressures resulting from the COVID-19 pandemic. Further research is required to 41 validate these findings with real world evidence; evaluate the broader clinical and economic impact of 42 the test; and to determine outcomes and risks for patients deemed to be low-risk on the PinPoint test 43 and therefore not initially referred.

44

## 45 **Key words:** Breast Neoplasms; Secondary Care Centres; Computer Simulation

## 46 **Declarations**

- 47 **1. Ethics approval and consent to participate**
- 48 Not applicable (no human participants were involved in this research).
- 49 **2. Consent for publication**
- 50 Not applicable.
- 51 **3. Availability of data and materials**
- 52 The simulation model generated during the current study is available from the corresponding author
- 53 upon reasonable request.
- 54 **4. Competing interests**

55 AS, SF, RN and BS work at the University of Leeds. NS and LH work at the Leeds Teaching 56 Hospitals NHS Trust (LTHT). Both the University of Leeds and the LTHT have a royalty agreement 57 with PinPoint Data Science Ltd, meaning that those institutions are likely to benefit financially in the 58 event of the PinPoint test being commercially successful.

59 **5. Funding** 

60 This work was funded by an Innovate UK Digital Health Technology Catalyst grant, as part of the 61 Industrial Strategy Challenge fund (project number: 105411). AS, SF, RN, LH and BS are supported 62 by the NIHR In-Vitro Diagnostics Evidence Co-operative (MIC). RN and BS are supported by the 63 CRUK CanTest Collaborative (grant number: C8640/A23385).

## 64 **6. Authors contributions**

65 AS conducted the data analysis for the model, developed and parameterised the model, analysed the 66 model results, and was the primary author of the manuscript. SF provided input on the model 67 development and parameterisation. NS provided clinical data for the model, supervised the data 68 analysis, and clinically validated the model. RN provided clinical oversight throughout the 69 development and analysis of the model. LH provided PLICS data for the model and supervised the

- 70 data analysis. BS provided supervision throughout the model development and analysis. All authors
- 71 contributed to the drafting and finalisation of the manuscript.

## 72 **7. Acknowledgements**

- 73 Not applicable.
- 74
- 75 **Word count = 4,138** (excluding tables and references)

## 76 **Background**

77 The "two-week wait" (TWW) pathway for breast cancer, which stipulates that patients with suspected 78 cancer symptoms should be seen in secondary care within two weeks of their first GP presentation, 79 was first introduced in the UK in 1999 in response to the country's poor breast cancer mortality 80 statistics (1). Based on concerns over the number of cancer cases continuing to be identified via 81 routine "symptomatic" referrals (i.e. where breast cancer is not initially suspected) (2), the TWW 82 pathway was subsequently extended to all patients with breast symptoms (i.e. not limited to 83 recognised cancer symptoms) (3). Similar TWW referral pathways are now in place for all major 84 cancers, with over two million TWW referrals occurring annually across England alone (4).

85 The last five years has seen a sharp rise in TWW referrals for breast cancer, from just under 542,000 86 across England in 2015/16, to over 612,000 in 2019/20 (a rise of almost 13%) (5, 6). Unsurprisingly, 87 breast cancer clinics are struggling to cope with the increased demand. Since 2018, the government's 88 operational standard target – that 93% of patients should be seen within fourteen days of referral – has 89 not been achieved, and the ongoing COVID-19 pandemic has resulted in a further drop in recent 90 adherence to this target (6-9). At the same time, whilst regional variation in cancer prevalence rates 91 exists, less than 7% of patients referred along TWW cancer referral pathways are ultimately 92 diagnosed with cancer, suggesting that many of these referrals could be avoided (10). Strategies to 93 identify patients who do not require further investigation are urgently required to alleviate pressure on 94 breast cancer clinics.

95 In collaboration with the Leeds Teaching Hospitals NHS Trust (LTHT) and the University of Leeds, 96 PinPoint Data Science Ltd have developed a risk assessment tool, which is designed to determine 97 patients' risk of breast cancer based on a number of routine blood tests (including haematological, 98 biochemical and tumour markers). These individual tests are combined within an algorithm 99 (henceforth referred to as the "PinPoint test") to provide a calibrated risk probability of cancer (a 100 score between zero and one, with higher values indicating higher risk) (11). The PinPoint test can be 101 undertaken around the time of referral, providing utility for two main use-cases: (1) as a rule-out test 102 for patients with very low risk of cancer (i.e. avoiding secondary care referrals in this group); and (2)

103 as a tool to prioritise high risk patients (i.e. fast-tracking referrals for these patients). Thus far, early 104 diagnostic accuracy evidence suggests that for use-case (1) the test could avoid 20% of unnecessary 105 referrals, thus freeing up secondary care resources to focus on expediated diagnosis for those most at 106 risk (12).

107 Prior to commencement of the current study, initial discussions were undertaken with local 108 commissioners at Leeds (the Leeds Clinical Commissioning Group [CCG]), in order to determine 109 decision makers' primary requirements for adopting new interventions in this field. Based on that 110 work, the ability of new technologies to alleviate increasing pressure on secondary care services was 111 identified as a primary concern for clinical decision makers and commissioners. The aim of this early 112 exploratory evaluation was therefore to assess the potential impact of the PinPoint test on the flow of 113 patients through clinic services (focusing on use-case (1)), evaluating two primary outcomes: (i) the 114 percentage of patients seen in the clinic in under two weeks, and (ii) the number of 'overspill' 115 appointments generated (i.e. where patients have to return to the clinic for further diagnostics due to 116 insufficient same-day clinic capacity). Together these outcomes represent how well the referral 117 system achieves timely diagnoses for patients within an efficiently functioning system.

118 Discrete event simulation (DES) is a useful modelling technique which enables simulation of 119 individual entities (e.g. patients) through complex systems of activities (e.g. hospital services). With 120 the inclusion of activities dependent on constrained resources (e.g. staff, rooms, devices), the 121 possibility of queues forming in the system, leading to patient delays, can also be captured. Whilst 122 predominantly used in the context of manufacturing and engineering, the use of DES in healthcare has 123 been rising – with common applications including systems operation research, and disease 124 progression modelling (13, 14). In the context of breast cancer services, most DES applications to 125 date have focused on identifying optimal timings and/or technologies for breast cancer screening 126 programs, without consideration of capacity constraints (15-19). Notable exceptions include two 127 evaluations of mammography facilities – one in Brazil (20), the other USA (21) – which each 128 modelled the flow of patients through mammography services to determine optimal routine staffing 129 and equipment compositions. Similar methods are applied herein to instead explore the potential

130 utility of a new intervention, the PinPoint test, for improving patient workflow in secondary care

131 breast cancer clinics.

#### 132 **Methods**

133 Our reporting of the study methods below adheres to good practice guidelines as outlined in the 134 Strengthening The Reporting of Empirical Simulation Studies (STRESS) checklist for DES models 135 (22). Please see **Additional File 4** for the completed STRESS-DES checklist.

## 136 *Model Structure*

137 A DES model was constructed in Simul8 (https://www.simul8.com) to reflect the flow of patients 138 through the Leeds Teaching Hospitals Trust (LTHT) breast cancer clinic: a medium-to-large sized 139 clinic which sees around 10,500 patients along the TWW pathway annually. The model tracks 140 individual patients from their initial GP presentation, through to clinic services (including initial 141 assessment, mammogram, ultrasound and biopsy), accounting for available clinic resources (e.g. staff 142 and clinic rooms). Patients exit the model with a final diagnosis of breast cancer (following a multi-143 disciplinary team [MDT] meeting) or no breast cancer.

144 In the standard care arm (see **Figure 1** for the model schematic), all patients receive a referral to the 145 clinic at their initial GP appointment; whilst in the PinPoint arm, referrals are based on whether 146 patients receive a low- or high-risk PinPoint test result (see **Figure 2** for an illustration of the 147 implementation pathway for the PinPoint test). Due to current uncertainty around the exact impact of 148 PinPoint testing on standard care (particularly around the management and behaviour of patients with 149 low-risk results), different scenarios are explored (see the *Analysis* section). Depending on the number 150 of patients already in the queue for the clinic, referred patients have to wait for a period of time for the 151 next available slot; similarly once in the clinic, patients must wait for the required staff and rooms to 152 be available in order to undergo their required investigations.

153 A warm-up period of twelve weeks is initially applied in the model to populate the service queues (i.e. 154 rather than starting with an empty system). The subsequent results collection period lasts one year, 155 and is intended to capture service demand levels matching those observed at the LTHT clinic in 2019.

# 156 *Model Parameters*



# 174 **Table 1. Proportion of patients following different sequences of breast cancer clinic diagnostic**  activities



a For pathways involving mammogram and ultrasound, the proportion undergoing mammogram first was set to 60%, vs. 40% for ultrasound first in the model, based on expert clinical opinion. <sup>b</sup>Cases listed under the heading 'other' in this data extract  $[N=125$  in total] were excluded from this analysis. PLICS = Patient Level Information and Costing System

176

177 In line with the LTHT clinic schedule, the model includes seven weekly 'full' clinics (Mon AM, Tues 178 PM, Weds AM & PM, Thurs AM & PM, and Fri AM), and one weekly 'add-on' clinic with a reduced 179 capacity (Tues AM; this clinic was first introduced in early 2018 as a temporary measure to alleviate 180 pressure on the clinic, but has since been permanently adopted due to persisting demand). All clinics 181 last four hours (AM = 09:00 to 13:00; PM = 14:00 to 18:00), with up to fifteen minutes of staff 182 overtime allowed to complete activities if necessary. The clinic staff includes radiological and 183 surgical staff (consultants, nurse practitioners [NPs] and physician associates [PAs]); and 184 radiographer staff (Band 6 sonographers and non-sonographers, Band 7 sonographers and Grade 2 185 assistants). Staff numbers were set to match the LTHT staff schedule, and staff availability within 186 shifts was set based on expert opinion as to the amount of time each staff member would typically 187 spend on 'other' activities (e.g. administrative tasks and follow-up appointments) (see **Additional**  188 **files 1** and **2**). Patients are not assigned to a specific member of staff – rather, as soon as any relevant 189 staff member becomes available for the patient's next required activity, the patient can undergo that 190 activity.

191 Based on consultation with LTHT clinic staff, the default number of new patients booked into each 192 clinic was set to twenty-five for full clinics, and ten for the Tues AM add-on clinic. Whilst these are 193 the 'target' clinic numbers, the clinic audit data indicated that the full clinic numbers could fluctuate 194 (little variation was observed in the Tues AM clinic). It was confirmed that full clinic numbers would 195 be increased in response to periods of higher demand, in an attempt to meet the TWW target. In the 196 model therefore, above a clinic queue of 380 (i.e. slightly above the number that can be seen over two 197 weeks at the default clinic numbers), the number of new patients booked into the next full clinic was 198 allowed to increase by 1 for every additional 15 patients in the queue, up to a maximum of 34. The 199 clinic numbers thus reflect a degree of 'responsiveness' to the queue, in line with real-life practice. 200 This approach was able to produce similar proportions of patients meeting the TWW target in the

201 model standard care arm (66.3%), as seen in NHS referral data for the Leeds CCG in 2019 (66.5%) 202 (23). All queues in the system were set to operate on a 'first in first out' basis – such that those 203 patients waiting the longest in queues are always the first to be selected for the associated activity. 204 Clinics may close with patients still waiting in the activity queues. In this case, the 'overspill' patients 205 are routed out of the clinic and placed in a queue to return to the clinic at a later date. Based on the 206 audit data, five appointments are typically reserved per LTHT full clinic to see overspill patients from 207 previous clinics, with a slightly higher number (six) observed for the Tues AM clinic. The model

208 therefore allows up to five and six overspill patients to be seen per full clinic and Tues AM clinic 209 respectively (in addition to new patients).

210 The maximum number of each clinic activity able to be undertaken at any given time was based on 211 the number of rooms (each with one available imaging device) available at the LTHT clinic (four 212 initial assessment; three mammogram; four ultrasound; and four biopsies). The actual number of each 213 activity undertaken at any point depends also on the availability of staff: an activity can only go ahead 214 if both a room and required staff are available. The median times taken to complete each activity was 215 based on expert opinion (initial assessment  $= 10$  minutes; mammogram  $= 20$  minutes; ultrasound  $= 20$ 216 minutes; biopsy = 30 or 45 minutes [each with 50% chance of occurring]), allowing for some 217 variation around the expected timings (see **Additional File 1**).

218 The sensitivity (0.98) and specificity (0.20) values applied for the Pinpoint test were provided by the 219 manufacturer, based on an unpublished test development and validation study. This study included 220 data on a total of n=14,021 patients referred along the TWW pathway for breast cancer at LTHT, 221 between 2011-16 [study development set] and 2017-19 [study validation set]). Full details of this 222 study are now available in a published manuscript (12). Other key parameters for the Pinpoint arm 223 were altered within scenario and secondary analyses, as outlined further below.

#### 224 *Validation*

225 Face validity of the model was checked via a series of consultations with clinicians at the LTHT 226 clinic. Internal validity of the model code was confirmed using extreme value tests, and using the

227 Simul8 inbuilt 'Simulation Monitor' function. Finally, external validity of the model was determined 228 by comparing primary baseline results from the model against real world data: (i) the simulated 229 proportion of patients meeting the TWW target (66.3%) were compared against NHS England data for 230 the same time period (66.5%) (23); and the number of simulated overspill appointments ( $N=1,685$ ) 231 were compared against the annual value reported in the LTHT audit data  $(N=1,664)$ .

232 *Analysis* 

233 All results are based on 150 model trials (i.e. running the model 150 times, using different random 234 number sequences), and using deterministic analysis (i.e. probabilistic sensitivity analysis was not 235 conducted due to the early nature of this analysis). The number of trials and warm-up period were set 236 to a level sufficient to produce stable model outputs (ascertained by visual inspection of plotted model 237 outputs).

238 For Pinpoint, due to current uncertainty as to the exact impact of the test on standard care, two 239 primary scenarios were explored:

240 • **Scenario 1**: GPs only refer patients with high-risk results (i.e. 100% adherence to testing), and 241 all patients with cancer who receive a low-risk test result are assumed to return after 6 weeks 242 with persisting symptoms and receive a delayed clinic referral.

243 • **Scenario 2**: GPs overrule 20% of low-risk results (cancerous and non-cancerous cases), and a 244 further 10% of patients without breast cancer with a low-risk test result are also assumed to 245 return and receive a delayed referral at six weeks.

246 In addition to the above, based on the premise that Pinpoint could significantly reduce referrals and 247 free up clinic capacity, the following service reconfiguration scenarios were explored: (1) removing 248 the Tues AM add-on clinic; (2) removing a full clinic (arbitrarily chosen as Wed AM); and (3) 249 removing the Tues AM and Wed AM clinics. These options were applied together with the Pinpoint 250 Scenario 2 parameters. A range of secondary analyses were also conducted to explore the impact of 251 altering the levels of GP adherence, delayed referrals, diagnostic accuracy, cancer prevalence and 252 patient arrivals (see **Additional File 3**).

253

## 254 **Results**

#### 255 *Referral patterns*

256 Based on average simulated patient numbers over 150 model runs, under standard care, 100% 257 (n=10,528) of patients receive an immediate referral. With Pinpoint, 81% (n=8,544/ 10,550) of 258 patients completing the model were referred under Scenario 1: this included all patients with breast 259 cancer (n=505), 2% (n=10) of whom received a delayed (rather than immediate) referral; and 80% 260 (n=8,039/10,044) of patients without cancer (all referred immediately). Under Scenario 2, 86% 261 (n=9,107/10,550) of patients received a referral: all patients with breast cancer (n=505), 2% (n=8) of 262 whom received a delayed referral; and 86% (n=8,602/ 10,044) of patients without breast cancer, 2% 263 (n=161) of whom also received a delayed referral. Note that in both scenarios, the average number of 264 patients completing the model in the PinPoint arm is higher than in the standard care arm, due to the 265 fact that more patients remain in the system queues (i.e. the TWW referral queue, and the overspill 266 Clinic Returns queue) at the end of the simulation in the standard care arm compared to the PinPoint 267 arm.

#### 268 *Primary outcomes*

269 **Table 2** shows that the reduction in referrals achieved with the PinPoint test is expected to shorten the 270 time to clinic for those referred, by three to four days on average. Consequently the percentage of 271 patients seen in the clinic in under two weeks is increased, from around 66% with standard care, to 272 between 100 (Scenario 1) and 98% (Scenario 2) with the Pinpoint test. Overspill cases are also 273 reduced – from an average of 1,685 with standard care (a number which closely matches the number 274 of overspill appointments recorded in the LTHT 2019 audit data i.e. n=1,664), to between 727 275 (Scenario 1) or 886 (Scenario 2) with Pinpoint.

276 **Table 2** further illustrates that, applying the Scenario 2 parameters, the reduction in referrals achieved 277 with the Pinpoint test is sufficient to allow the Tues AM add-on clinic to be removed from the weekly 278 clinic schedule: this option maintains the percentage meeting the TWW target at close to 95%, and

- 279 keeps the overspill cases (n= 1,292) well below that seen with standard care (albeit higher than the
- 280 PinPoint main scenario analyses). Any further reductions to the schedule are not tolerated however,
- 281 with the removal of the full Wed AM clinic resulting in less than 3% of patients meeting the TWW
- 282 requirement and high overspill numbers  $(n = 1,632)$ .





 $BC =$  breast cancer;  $CI =$  confidence interval.

284 The results were robust to the secondary analyses explored (see **Additional file 3**). The incremental 285 benefits associated with the PinPoint test were slightly reduced when (a) increasing the proportion of 286 GP overrides up to 50%, or (b) increasing the proportion of non-cancerous patients receiving a 287 delayed referral up to 50%; however the test maintained significantly higher TWW percentage values 288 and lower overspill numbers compared to standard care, across all of the secondary analyses 289 conducted. The test-based strategy was also more robust than standard care at coping with increased 290 patient numbers: for example, when increasing the number of patients arriving in the model by 10%, 291 the PinPoint test was able to maintain 99.9% of patients meeting the TWW target, with an average of 292 1,156 overspills; whilst the same scenario for standard care led to a drop in the overall percentage 293 meeting the TWW target (to 61.2%), with an average of 2,555 overspills.

## 294 **Discussion**

295 Based on early diagnostic accuracy data and clinical assumptions, the PinPoint test could provide 296 significant relief to breast cancer clinics, enabling the majority of referred patients to be seen within 297 two weeks and allowing more patients to receive their full sequence of diagnostic assessments in a 298 single clinic visit. It is further possible that this reduction in clinic demand could be sufficient to 299 remove the LTHT weekly add-on clinic, if the benefits of doing so (e.g. staff relief, cost savings, 300 shifting resources) could be considered to outweigh the associated costs (e.g. slightly lower 301 percentage of patients meeting the TWW target, and higher overspill numbers). It is of particular 302 interest to note that, whilst in simple terms the test is expected to remove 20% of patients from the 303 TWW pathway (based on its 20% specificity), this does not translate to being able to remove 20% of 304 the clinic schedule (i.e. one full clinic). This is because of the significant extra demand in workload 305 the department is already attempting to meet by regularly expanding their clinics to maximum 306 capacity; removing some of that excess demand means that clinics are more able to regularly run at 307 their intended (rather than maximum) capacity.

308 As with any early model-based analysis, this assessment has limitations. First, the model is based on 309 data from a single centre, and the results are therefore only expected to reflect the impact of the test 310 on similar medium-to-large sized clinics across the UK. The applicability of the findings to other

311 NHS clinics, particularly those of a different size or alternative configurations to the Leeds clinic, is 312 unclear. Second, due to the early nature of this assessment, several of the model parameters were set 313 based on expert opinion. Ideally a site visit to observe the actual flow of patients through the LTHT 314 clinic would have been undertaken, but was not possible due to the ongoing COVID pandemic. 315 Nevertheless, the availability of clinic audit data and the bespoke NHS PLICs dataset for Leeds 316 allowed most parameters to be set or validated against real world data. Most importantly for the 317 PinPoint arm, key assumptions had to be made around the management and behaviour of patients with 318 low-risk results, for which there is currently no available evidence. If and when further information on 319 these parameters becomes available, the model can be easily updated to provide a more precise 320 evaluation.

321 Additional uncertainty around the applicability of these findings stems from the ongoing fallout of the 322 COVID-19 pandemic, which has had a major impact on cancer referral patterns (24, 25). At the time 323 of analysis planning (mid 2020), the demand for breast cancer clinic services at the LTHT was 324 considered to be unpredictable due to the impact of successive national and regional "lock-downs". 325 Nevertheless, based on expert consultation, only a slight drop in patient numbers was observed over 326 the initial national lock-down period (early 2020), with numbers expected to quickly return to pre-327 pandemic levels following continued easing of restrictions. The decision was therefore made to base 328 the analysis on pre-pandemic data from 2019. Going forward, it is expected that referrals will likely 329 rise above pre-pandemic levels. If that expectation holds true, based on our early analysis the PinPoint 330 test would potentially be better enable secondary care breast cancer services to cope with such 331 increases in demand, and could therefore be of increased utility.

332 Whilst the findings of this exploratory study are encouraging, additional outcomes – most importantly 333 patient health outcomes and health-economic outcomes – would require evaluation before adoption of 334 the PinPoint test could be definitively recommended. Of particular concern is the clinical management 335 and outcomes for those 20% of patients initially ruled-out by the PinPoint test. This group was 336 explored in the current model via sensitivity analyses, which show how the model outcomes may 337 change if a higher proportion of initially discharged patients return to their GP for a later referral.

338 However, the potential impact on health outcomes for this group were not explored. Although this 339 group consists predominantly of patients without cancer, the significant risks associated with delayed 340 or missed diagnoses for those few patients with cancer is such that some form of safety-netting 341 guidance is expected to be required, in order to instil confidence that patient harm may be avoided. 342 Repeated testing and/or a follow-up GP visit could be implemented in this group, for example, as a 343 means of protection both for those patients with cancer, and for those patients without cancer who 344 may experience persisting symptoms resulting from other indications requiring further follow-up. 345 Clearly the implementation of any such safety-netting procedures would have an impact on both 346 healthcare costs and patient health outcomes. An early economic evaluation is currently underway to 347 explore the impact of different implementation scenarios core to the health-economic argument for the 348 use of the PinPoint test, compared to current practice. The findings of that analysis will help to 349 determine whether further primary research is required in order to address these aspects of 350 uncertainty.

351 The results of this early-stage evaluation were used to help secure further funding for a service 352 evaluation of the PinPoint test across multiple sites in Yorkshire (26). That project will aim to 353 determine the real-world performance of the test; establish the logistics of implementing the test in the 354 NHS; and update the early evaluation described herein, to address key uncertainties highlighted in the 355 analysis and incorporate cost and health outcomes data. The results of the service evaluation will be 356 reported to NHS England.

357 On a final note, alternative strategies have been suggested for reducing the burden on secondary care 358 services. Blacker and colleagues (27), for example, suggest that separate non-urgent clinics for breast 359 pain and breast lumps in patients aged under thirty could be set up, based on the low incidence of 360 cancer in this group. Ramzi and colleagues (28) have further demonstrated that using age as a single 361 referral criterion provides higher diagnostic accuracy than the TWW pathway, and would be expected 362 to be less costly. Other multi-variate prediction models, which avoid the need for any additional 363 laboratory-based tests, have also been suggested (29). The use of the PinPoint test as a prioritisation 364 test for referrals (i.e. use-case (2)), in addition to its role as a rule-out test, also deserves further





- 389
- 390

# 391 **Figure captions**

## 392 **Figure 1. Model figure for the standard care (no primary care testing) pathway (GP = general**

#### 393 **practitioner; TWW = two week wait; MDT = multi-disciplinary team)**

394 **Figure 1 Legend**: Patients with suspected breast cancer enter the model at the GP arrivals point. 395 Individual patients are then tracked through the model. The yellow box captures the activities of the 396 breast cancer clinic (i.e. initial assessment; mammogram; ultrasound and biopsy), which each depend 397 the availability of rooms and staff. Patients are required to wait in the activity queues until such a time 398 as an available room and required staff members are available. At the end of each scheduled clinic, 399 any patients left in the clinic activity queues are routed back around to the 'Clinic returns' activity and 400 will be required to attend a future clinic to finish their course of diagnostics. Once an individual's 401 clinic activities have been completed, the patient receives a diagnosis of cancer or no cancer, and exits 402 the model at the associated exit point.

403

404 **Figure 2. Expected implementation pathway for the PinPoint test (GP = general practitioner;**  405 **TWW = two week wait).** 

406

# 407 **List of abbreviations**

- $408$  BC = breast cancer
- 409 CCG = Clinical Commissioning Group
- $410$  CI = confidence interval
- $411$  DES = discrete event simulation
- 412 LTHT = Leeds Teaching Hospitals Trust
- 413 GP  $=$  General practitioner
- 414 MDT = multi-disciplinary team
- $415$  NP = nurse practitioner
- $416$  PA = physician associate
- 417 PLICS = Patient Level Information and Costing System
- 418 TWW = two-week wait
- 419 UK = United Kingdom

It is made available under a CC-BY-ND 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.06.13.22276333;](https://doi.org/10.1101/2022.06.13.22276333) this version posted June 16, 2022. The copyright holder for this preprint

## 420 **References**

421 patterns, cancer diagnoses, and waiting times after introduction of two week wait rule for breast<br>
2. Sauven P. Impact of the '2 week wait' on referrals to breast units in the UK. The Breast.<br>
2. Sauven P. Impact of the '2 422 cancer: prospective cohort study. BMJ. 2007;335(7614):288.<br>
2. Sauven P. Impact of the '2 week wait' on referrals to breast units in the UK. The Breast.<br>
2002;11(3):262-4.<br>
3. National Collaborating Centre for Cancer. Susp 423 2. Sauven P. Impact of the '2 week wait' on referrals<br>2002;11(3):262-4.<br>3. National Collaborating Centre for Cancer. Suspected<br>Guideline [NG12]. <u>https://www.nice.org.uk/guidance/ng12</u>.<br>4. NHS England. Annual NHS cancer ch 424 2002;11(3):262-4.<br>
3. National Collaborating Centre for Cancer. Suspected cancer: recognition and referral. NICE<br>
Guideline [NG12]. <u>https://www.nice.org.uk/guidance/ng12</u>. Accessed April 2021.<br>
4. NHS England. Annual NHS 425 3. National C<br>
Guideline [NG12].<br>
4. NHS Eng<br>
https://www.engla<br>
Accessed April 202<br>
5. NHS E<br>
https://www.engla<br>
reports/cancer-wa<br>
7. NHS E<br>
https://www.engla<br>
reports/cancer-wa<br>
7. NHS E<br>
https://www.engla<br>
reports/canc 426 Guideline (NG12). https://www.nice.org.uk/guidance/ng12. Accessed April 2021.<br>
4. MHS England. Annual NHS cancer checks top two million for the first time.<br>
https://www.england.nhs.uk/2019/04/annual-hhs-cancer-checks-top-t 427 4. MHS England. Annual NHS cancer checks top two million for<br>
https://www.england.nhs.uk/2019/04/annual-nhs-cancer-checks-top-two-million<br>
Accessed April 2021.<br>
5. NHS England. Cancer Waiting Times Annual Re<br>
https://www.e 428 2015-19. MHS England. Annual American Control and Meport, 2015-16.<br>
2. MHS England. Cancer Waiting Times Annual Report, 2015-16.<br>
2. MHS England. Cancer Waiting Times Annual Report, 2015-16.<br>
2. MHS England. Cancer Waiting 429 Accessed April 2021.<br>
S. MHS England. Cancer Waiting Times Annual Report, 2015-16.<br>
https://www.england.nhs.uk/statistics/statistical-work-areas/cancer-waiting-times/cwt-annual-<br>
reports/cwt-annual-report-2015-16/. Accesse 430 S. NHS Eng<br>
https://www.england<br>
reports/cwt-annual-r<br>
6. NHS Eng<br>
https://www.england<br>
reports/cancer-waitir<br>
7. NHS Eng<br>
https://www.england<br>
8. NHS Eng<br>
https://www.england<br>
reports/statistical-wd<br>
annual-report-2018-1<br> 431 2. NHS England. Instaktion (Material Work-areas/cancer-waiting-times/cwt-annual-reports/cwt-annual-report-2015-16/. Accessed April 2021.<br>
1. The England. Cancer Waiting Times Annual Report, 2019-20.<br>
2. NHS England. Instak 432 http://www.england.nhs.uk/statistics/statistical-work-areas/cancer-waiting-times. Accessed April<br>2021. 433 For MHS England. Cancer Waiting Tir<br>
https://www.england.nhs.uk/statistics/statistical-work-are<br>
reports/cancer-waiting-times-annual-report-2019-20/. Access<br>
7. NHS England. Cancer Waiting Tir<br>
https://www.england.nhs.uk/s 434 England. International and Market Statistics/statistics/statistics/statistics/statistics/statistics/statistics/statistics/statistics/ancer-waiting-times/cwt-annual-<br>reports/cancer-waiting-times-annual-report-2019-20/. Acce 435 Accessed April 2021.<br>12. Savage R, Messenger M, Neal RD, Ferguson R, Johnston C, Lloyd KL, et al. Development and 436 7. NHS England. Cancer Waiting Times Annual<br>
https://www.england.nhs.uk/statistics/statistical-work-areas/cancer-waiting<br>
reports/cancer-waiting-times-annual-report-2017-18/. Accessed April 2021.<br>
8. NHS England. Cancer Wa 437 2021.<br>
2. NHS England.nhs.uk/statistics/statistical-work-areas/cancer-waiting-times/cwt-annual-<br>
2. NHS England. Cancer Waiting Times Annual Report, 2018-19.<br>
2. NHS England.nhs.uk/statistics/statistical-work-areas/cancer-438 patients referred urgently from primary care: a diagnostic accuracy study. BMJ Open.<br>2022;12(4):e053590. 439 8. NHS England. Cancer Waiting Times Annual<br>
https://www.england.nhs.uk/statistics/statistical-work-areas/cancer-waiting<br>
reports/statistical-work-areas-cancer-waiting-times-cwt-annual-reports-can<br>
annual-report-2018-19/. 440 England. https://www.england.nhs.uk/statistics/statistical-work-areas/cancer-waiting-times/cwt-annual-<br>eports/statistical-work-areas-cancer-waiting-times-cwt-annual-reports-cancer-waiting-times-<br>emunal-report-2018-19/. Acc 441 health services research. 2018;18(1):1-11.<br>14. Vázquez-Serrano JI, Peimbert-García RE, Cárdenas-Barrón LE. Discrete-Event-Simulation 442 Modeling in Healthcare: A Comprehensive Review. International journal of environmental research 443 9. Nuffield Trust & The He<br>
https://www.nuffieldtrust.org.uk/resource/ca<br>
2021.<br>
10. NHS England. Cance<br>
http://www.england.nhs.uk/statistics/statistic<br>
2021.<br>
11. PinPoint Data Science Ltd. Early Cance<br>
Accessed April 202 444 https://www.nuffieldtrust.org.uk/resource/cancer-waiting-time-targets#background. Accessed April<br>2021. NHS England. Cancer Waiting Time Statistics.<br>http://www.england.nhs.uk/statistics/statistical-work-areas/cancer-waiting 445 2021.<br>
10. NHS England. Cancer Waiting Time Statistics.<br>
https://www.england.nhs.uk/statistics/statistical-work-areas/cancer-waiting-times. Accessed April<br>
2021.<br>
2021.<br>
2021. Savage R, Messenger M, Neal RD, Ferguson R, Jo 446 10.<br><u>http://</u><br>2021.<br>11.<br>Access<br>12.<br>validation<br>2022;<br>13.<br>health<br>14.<br>Model<br>and pu<br>15.<br>mamn 447 http://www.england.nhs.uk/statistics/statistical-work-areas/cancer-waiting-times. Accessed April<br>2021.<br>2021. PinPoint Data Science Ltd. Early Cancer Detection. https://www.pinpointdatascience.com/.<br>4Ccessed April 2021.<br>2. 448 2021.<br>
11. PinPoint Data Science Ltd. Early Cancer Detection. https://www.pinpointdatascience.com/.<br>
Accessed April 2021.<br>
12. Savage R, Messenger M, Neal RD, Ferguson R, Johnston C, Lloyd KL, et al. Development and<br>
12. S 449 -----<br>11.<br>Access<br>12.<br>validation<br>2022;<br>13.<br>health<br>14.<br>Model<br>15.<br>Assess<br>16.<br>analys<br>program 450 Accessed April 2021.<br>
12. Savage R, Messenger M, Neal RD, Ferguson R, Johnston C, Lloyd KL, et al. Development and<br>
validation of multivariable machine learning algorithms to predict risk of cancer in symptomatic<br>
2022;12( 451 12. Savage R, Me<br>
validation of multiva<br>
patients referred 1<br>
2022;12(4):e053590.<br>
13. Zhang X. Apr<br>
health services resea<br>
14. Vázquez-Serr<br>
Modeling in Healthca<br>
and public health. 20<br>
15. Bessen T, Ke<br>
mammographic foll 452 validation of multivariable machine learning algorithms to predict risk of cancer in symptomatic<br>patients referred urgently from primary care: a diagnostic accuracy study. BMJ Open.<br>2022;12(4):e053590.<br>13. Zhang X. Applica 453 patients referred urgently from primary care: a diagnostic accuracy study. BMJ Open.<br>2022;12(4):e053590.<br>13. Zhang X. Application of discrete event simulation in health care: a systematic review. BMC<br>health services resear 454 2022;12(4):e053590.<br>
2022;12(4):e053590.<br>
22022;12(4):e053590.<br>
health services research. 2018;18(1):1-11.<br>
14. Vázquez-Serrano JI, Peinbert-García RE, Cárdenas-Barrón LE. Discrete-Event Simulation<br>
14. Vázquez-Serrano JI 455 13. Zhang X. App<br>health services resear<br>14. Vázquez-Serra<br>Modeling in Healthca<br>and public health. 202<br>15. Bessen T, Ke<br>mammographic follo<br>Assessment in Health<br>16. Comas M, Al<br>analysis of switching<br>program: a discrete e<br>17. 456 13. Victor of Mathematical Mathematical Adolescent Simulation Nodeling in Health Sevice Serarao JI, Peimbert-García RE, Cárdenas-Barrón LE. Discrete-Event Simulation Modeling in Health. 2021;18(22):12262.<br>
15. Bessen T, Ke 457 14. Vázquez-Serrano JI, Peimbert-Ga<br>
Modeling in Healthcare: A Comprehensive<br>
and public health. 2021;18(22):12262.<br>
15. Bessen T, Keefe DM, Karnon J. I<br>
mammographic follow-up schedules, by<br>
Assessment in Health Care. 201 458 Modeling in Healthcare: A Comprehensive Review. International journal of environmental research<br>and public health. 2021;18(22):12262.<br>15. Bessen T, Keefe DM, Karnon J. Does one size fit all? Cost utility analyses of altern 459 and public health. 2021;18(22):12262.<br>15. Bessen T, Keefe DM, Karnon J. Does one size fit all? Cost utility analyses of alternative<br>mammographic follow-up schedules, by risk of recurrence. International Journal of Technolo 460 and public health Transport (11, Karnon<br>15. Bessen T, Keefe DM, Karnon<br>mammographic follow-up schedules,<br>Assessment in Health Care. 2015;31(5)<br>16. Comas M, Arrospide A, Mar<br>analysis of switching to digital mam<br>program: a d 461 mammographic follow-up schedules, by risk of recurrence. International Journal of Technology<br>
Assessment in Health Care. 2015;31(5):281-8.<br>
16. Comas M, Arrospide A, Mar J, Sala M, Vilaprinyó E, Hernández C, et al. Budget 462 Assessment in Health Care. 2015;31(5):281-8.<br>
16. Comas M, Arrospide A, Mar J, Sala M, Vilaprinyó E, Hernández C, et al. Budget impact<br>
analysis of switching to digital mammography in a population-based breast cancer scree 463 Assessment in Health Comas M, Arrospide A, Mar J, Sala<br>analysis of switching to digital mammogra<br>program: a discrete event simulation model. P<br>17. Furzer J, Tessier L, Hodgson D, Cotto<br>Breast Cancer Surveillance in Survivo 464 16. Comas Mary Sis of Switching to digital mammography in a population-based breast cancer screening<br>
16. Comas Mary J, Terzer J, Tessier L, Hodgson D, Cotton C, Nathan PC, Gupta S, et al. Cost-Utility of Early<br>
17. Furzer 465 program: a discrete event simulation model. PLoS One. 2014;9(5):e97459.<br>
17. Furzer J, Tessier L, Hodgson D, Cotton C, Nathan PC, Gupta S, et al. Cost-Utility of Early<br>
Breast Cancer Surveillance in Survivors of Thoracic R 466 program: Furzer J, Tessier L, Hodgson D, Cotton C, Nathan PC, Gupta S,<br>Breast Cancer Surveillance in Survivors of Thoracic Radiation-Trea<br>Lymphoma. J Natl Cancer Inst. 2020;112(1):63-70.<br>21 467 Breast Cancer Surveillance in Survivors of Thoracic Radiation-Treated Adolescent Hodgkin<br>Lymphoma. J Natl Cancer Inst. 2020;112(1):63-70.<br>21 468 Lymphoma. J Natl Cancer Inst. 2020;112(1):63-70.<br>21 469  $\frac{1}{2}$ 

It is made available under a CC-BY-ND 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.06.13.22276333;](https://doi.org/10.1101/2022.06.13.22276333) this version posted June 16, 2022. The copyright holder for this preprint

470 18. 471 472

473 474 475

effectiveness of combined digital mammography and tomosynthesis screening for women with<br>dense breasts. Radiology. 2015;274(3):772-80.<br>19. Stout NK, Rosenberg MA, Trentham-Dietz A, Smith MA, Robinson SM, Fryback DG.<br>Retros dense breasts. Radiology. 2015;274(3):772-80.<br>
19. Stout NK, Rosenberg MA, Trentham-Dietz A, Smith MA, Robinson SM, Fryback DG.<br>
Refrequences Cost-effectiveness Analysis of Screening Mammography. JNCl: Journal of the Natio 19. Stout NK, Rosenberg MA, Trentham<br>Retrospective Cost-effectiveness Analysis of Sc<br>Cancer Institute. 2006;98(11):774-82.<br>20. Coelli FC, Ferreira RB, Almeida RMV, P<br>models in the analysis of a mammography clir<br>biomedicine Extrospective Cost-effectiveness Analysis of Screening Mammography. JNCI: Journal of the National<br>Cancer Institute. 2006;98(11):774-82.<br>20. Coelli FC, Ferreira RB, Almeida RMV, Pereira WCA. Computer simulation and discrete 476 477 478

479 480 481

482 483 484

485 486 487

Cancer Institute. 2006;98(11):774-82.<br>
20. Coelli FC, Ferreira RB, Almeida RMV, Pereira WCA. Computer simulation and discrete-event<br>
models in the analysis of a mammography clinic patient flow. Computer methods and program 20. Coelli FC, Ferreira RB, Almeid<br>
models in the analysis of a mammogloiomedicine. 2007;87(3):201-7.<br>
21. Amir T, Lee B, Woods RW, M<br>
potential for improved efficiency in a<br>
2019;32(2):221-7.<br>
22. Monks T, Currie CS, Ongg models in the analysis of a mammography clinic patient flow. Computer methods and programs in<br>biomedicine. 2007;87(3):201-7.<br>21. Amir T, Lee B, Woods RW, Mullen LA, Harvey SC. A pilot of data-driven modeling to assess<br>pote biomedicine. 2007;87(3):201-7.<br>
21. Amir T, Lee B, Woods RW, Mullen LA, Harvey SC. A pilot of data-driven modeling to assess<br>
2019;32(2):221-7.<br>
2019;32(2):221-7.<br>
22. Monks T, Currie CS, Onggo BS, Robinson S, Kunc M, Tayl 21. Amir T, Lee B, Woods R<br>potential for improved efficienc<br>2019;32(2):221-7.<br>22. Monks T, Currie CS, Ong<br>empirical simulation studies:<br>2019;13(1):55-67.<br>23. NHS England. 2018<br>https://www.england.nhs.uk/state<br>cwt/2018-19-m potential for improved efficiency in an academic breast-imaging center. Journal of Digital Imaging.<br>2019;32(2):221-7.<br>22. Monks T, Currie CS, Onggo BS, Robinson S, Kunc M, Taylor SJ. Strengthening the reporting of<br>empirica potential simulation studies: Introducing the STRESS guidelines. Journal of Simulation studies: Introducing the STRESS guidelines. Journal of Simulation.<br>2019;13(1):55-67.<br>2019;13(1):55-67.<br>23. NHS England. 2018/19 Monthly 22. Monks T, (<br>22. Monks T, (<br>2019;13(1):55-67.<br>23. NHS Eng<br>https://www.engla<br>cwt/2018-19-mont<br>24. Gathani T,<br>cancer diagnoses:<br>2021;124(4):710-2<br>25. Dave RV,<br>management path<br>of the B-MaP-C stu<br>https://cancerallia<br>Accessed empirical simulation studies: Introducing the STRESS guidelines. Journal of Simulation.<br>2019;13(1):55-67.<br>22. MHS England. 2018/19 Monthly Provider Cancer Waiting Times Statistics.<br>https://www.emgland.nhs.uk/statistics/sta 2019;13(1):55-67.<br>
23. NHS England. 2018/19 Monthly Provider Cancer Waiting Times Statistics.<br>
https://www.emgland.nhs.uk/statistical-work-areas/cancer-waiting-times/monthly-prov-<br>
cwt/2018-19-monthly-provider-cancer-waiti 23. NHS Eng<br>
23. NHS Eng<br>
https://www.engla<br>
24. Gathani T,<br>
cancer diagnoses:<br>
2021;124(4):710-2<br>
25. Dave RV,<br>
management path<br>
of the B-MaP-C stu<br>
26. West Y<br>
https://cancerallia<br>
Accessed May 202<br>
27. Blacker S,<br>
to pr https://www.england.nhs.uk/statistics/statistical-work-areas/cancer-waiting-times/monthly-provider-<br>cwt/2018-19-monthly-provider-cancer-waiting-times-statistics/. Accessed April 2021.<br>24. Gathani T, Clayton G, MacInnes E, 24. Gathani T, Clayton G, MacInnes E, Horgan K. The COVID-19 pandemic and in<br>
cancer diagnoses: what happened in England in the first half of 2020. British Jou<br>
2021;124(4):710-2.<br>
25. Dave RV, Kim B, Courtney A, O'Connell 488 489 490

491 492 493

494 495 496

cancer diagnoses: what happened in England in the first half of 2020. British Journal of Cancer.<br>2021;124(4):710-2.<br>25. Dave RV, Kim B, Courtney A, O'Connell R, Rattay T, Taxiarchi VP, et al. Breast cancer<br>management pathw 2021;124(4):710-2.<br>
2021;124(4):710-2.<br>
25. Dave RV, Kim B, Courtney A, O'Connell R, Rattay T, Taxiarchi VP, et al. Breast cancer<br>
management pathways during the COVID-19 pandemic: outcomes from the UK 'Alert Level 4' phas 25. Dave RV, K<br>25. Dave RV, K<br>management pathw<br>of the B-MaP-C stuc<br>26. West Yo<br>https://cancerallian<br>Accessed May 2022<br>27. Blacker S, Jo<br>to prioritise high r<br>Oncology. 2020;46(<br>28. Ramzi S, Ca<br>patient age and a pr<br>29. Galvi management pathways during the COVID-19 pandemic: outcomes from the UK 'Alert Level 4' phase<br>of the B-MaP-C study. British Journal of Cancer. 2021:1-10.<br>26. West Yorkshire and Harrogate Cancer Alliance. The PinPoint Test<br>t of the B-MaP-C study. British Journal of Cancer. 2021:1-10.<br>
26. West Yorkshire and Harrogate Cancer Alliance. The PinPoint Test<br>
https://canceralliance.wyhpartnership.co.uk/our-work/innovations-programme/pinpoint-test.<br>
A 26. West Yorkshire and Harrogate Cance<br>
https://canceralliance.wyhpartnership.co.uk/our-work/inne<br>
Accessed May 2022.<br>
27. Blacker S, Jordache R, Pakzad F. P029: Can two we<br>
to prioritise high risk patients for early diagn https://canceralliance.wyhpartnership.co.uk/our-work/innovations-programme/pinpoint-test.<br>Accessed May 2022.<br>27. Blacker S, Jordache R, Pakzad F. P029: Can two week wait breast cancer referrals be triaged<br>to prioritie high Accessed May 2022.<br>
27. Blacker S, Jordache R, Pakzad F. P029: Can two week wait breast cancer referrals be tto prioritise high risk patients for early diagnosis and treatment? European Journal of St<br>
20. Ramzi S, Cant P. 27. Blacker S, Jol<br>27. Blacker S, Jol<br>to prioritise high ris<br>Oncology. 2020;46(6<br>28. Ramzi S, Can<br>patient age and a pre<br>29. Galvin R, Joy<br>clinical prediction rul<br>2014;14(1):1-8. 497 498 499

500 501

29. Galvin R, Joyce D, Downey E, Boland F, Fahey T, Hill AK. Development and validation of a<br>clinical prediction rule to identify suspected breast cancer: a prospective cohort study. BMC cancer. to prioritise high risk patients for early diagnosis and treatment? European Journal of Surgical<br>Oncology. 2020;46(6):e18.<br>28. Ramzi S, Cant P. Comparison of the urgent referral for suspected breast cancer process with Oncology. 2020;46(6):e18.<br>
28. Ramzi S, Cant P. Comparison of the urgent referral for suspected breast cancer process with<br>
patient age and a predictive multivariable model. BJS open. 2021;5(2):zraa023.<br>
29. Galvin R, Joyc 28. Ramzi S, Cant P. Co<br>28. Ramzi S, Cant P. Co<br>patient age and a predictive<br>29. Galvin R, Joyce D,<br>clinical prediction rule to io<br>2014;14(1):1-8. patient age and a predictive multivariable model. BJS open. 2021;5(2):zraa023.<br>29. Galvin R, Joyce D, Downey E, Boland F, Fahey T, Hill AK. Development and validation of a<br>clinical prediction rule to identify suspected bre patient age and a prediction and a prediction rule to identify suspected breast cancer: a prospective cohoronal prediction rule to identify suspected breast cancer: a prospective cohoronal prediction rule to identify suspe 502 29. Galvin R, Joyce D, Downey E, Boland F, Fahey T, Hill AK. Development and validation of a 503  $c$ 014;14(1):1-8.<br> $c$ 014;14(1):1-8. 504 2014;14(1):1-8.

505

It is made available under a CC-BY-ND 4.0 International license.





![](_page_23_Figure_0.jpeg)